Study of a single-dose cholesterol drug after stent placement
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a single injection of a PCSK9 inhibitor (a cholesterol-lowering medicine) can improve heart health after a stent procedure. It is for people who have a certain amount of fat buildup in their treated artery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have coronary artery disease (with or without symptoms, stable chest pain, or a recent heart attack).
- You had a stent placed with a special imaging test called NIRS-IVUS.
- The imaging shows a specific level of fat in your treated artery (maxLCBI4mm of 200 or higher).
- You are able to give written permission to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a powerful cholesterol-lowering drug (PCSK9 inhibitor) helps stabilize plaque in heart arteries after a recent heart attack or unstable angina treated with a stent. It may lower the risk of future heart problems.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
This study tests whether starting a cholesterol-lowering drug called a PCSK9 inhibitor soon after a heart attack can help prevent future blockages. If you had a heart attack, received a stent, and have other arteries with minor blockages, this trial may be for you.
This trial looks at whether stronger cholesterol-lowering medicine can reduce the risk of future heart problems in people who already have a stent. It focuses on people who still have other mildly narrowed spots in their arteries.
This trial tests if adding a PCSK9 inhibitor (a newer cholesterol-lowering medicine) to standard care helps people who had a stroke from a large artery blockage and had a clot-removal procedure. It may lower bad cholesterol further and reduce the risk of another stroke.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.